Amardeep Singh

Principal Analyst

Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021

Clarivate oncology experts analyzed ASCO 2021 abstracts from Mainland China to highlight key trends and breakthrough treatments that are expected to impact the oncology landscape. Mainland Chinese companies were strongly represented at the 2021 ASCO Annual Meeting. As part of our Drugs to Watch™ series spotlighting therapies expected to have significant impact on drug landscapes, […]

Mainland China’s NRDL: The expensive yet priceless ticket to market access

Recent updates in the NRDL highlight Mainland China’s improving market access and reimbursement environment for innovative therapies. However, this comes at the cost of heavy price cuts that manufacturers must offer in exchange for NRDL inclusion. Are these price cuts worth gaining market access in Mainland China? What other trends have emerged from the recent […]